ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 43rd Annual Growth Conference at the InterContinental Boston Hotel. Management is scheduled to present on Wednesday, August 9, 2023, at 5:00 p.m. Eastern Standard Time.
Event: Canaccord Genuity 43rd Annual Growth Conference
Date: Wednesday, August 9, 2023
Time: 5:00 p.m. ET
A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
631-807-1986
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$142.62 |
Daily Change: | -0.42 -0.29 |
Daily Volume: | 285,618 |
Market Cap: | US$4.790B |
February 27, 2025 February 18, 2025 October 28, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load